Evaluation of efficacy and safety of Bacillus coagulans SNZ 1969 supplementation for irritable bowel syndrome: a randomized, double-blind, placebo-controlled study

Background: Probiotic potential (efficacy and safety) of Bacillus coagulans SNZ 1969 has been studied in patients with constipation-predominant irritable bowel syndrome (IBS-C) and-diarrhea predominant IBS (IBS-D).Methods: This randomized, double-blind, two-arm, placebo-controlled parallel study randomized 92 (1:1) to receive either 500 million CFU (treatment group) or placebo (placebo twice daily for 60 days under two subtypes IBS, IBS-D (n=46) IBS-C (n=46). Primary outcomes were changes symptom severity noted using the gastrointestinal rating scale-IBS version (GSRS-IBS) on 30, 60, 75, number treatment responders defined by subject’s global assessment (SGA) relief ≤3 ≤2 at 30 respectively. We also assessed patient’s quality life.Results: The GSRS-IBS scores reduced from day through 75 both groups treated SNZ1969 compared (p<0.05). Higher score was group (22.45±2.7) than (3.55±3.02; p<0.0001), this trend similar (p<0.0001). Most (90%) all responded no SF-8 significantly receiving subtypes. One adverse event unrelated treatments reported group.Conclusions: is safe, effective alleviating IBS-associated clinical symptoms, improves life.